AR056042A1 - Inhibidores de la map quinasa p38 y metodos para utilizarla - Google Patents

Inhibidores de la map quinasa p38 y metodos para utilizarla

Info

Publication number
AR056042A1
AR056042A1 ARP060103657A ARP060103657A AR056042A1 AR 056042 A1 AR056042 A1 AR 056042A1 AR P060103657 A ARP060103657 A AR P060103657A AR P060103657 A ARP060103657 A AR P060103657A AR 056042 A1 AR056042 A1 AR 056042A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
heteroalkyl
heterocyclyl
aryl
Prior art date
Application number
ARP060103657A
Other languages
English (en)
Inventor
Nidhi Arora
Humberto Bartolome Arzeno
Roland Joseph Billedeau
Nolan James Dewdney
Kieran Durkin
Kurt D Gabrielson
Kristen Lynn Mccaleb
Michael Soth
Dennis Mitsugu Yasuda
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37651018&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR056042(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR056042A1 publication Critical patent/AR056042A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Reivindicacion 1: Un compuesto con las formulas (1) o (2), o una sal farmacéuticamente aceptable del mismo, en el que: R1 es arilo or heteroarilo; R2 es -NRiRa, -NRiSO2Ra, -NRiC(=O)Ra, alquilsulfonamidilC1-6-alquiloC1-6, alcoxicarbonilaminoC1-6- alquiloC1-6, alquilo C3-6 lineal, alquenilo Cl 6, cicloalquilC3-7-alquiloC1-4, cicloalquenilo C3-7, cicloalquenilC3-7-alquiloC1-4, halo-alquiloC1-6, halocicloalquilo C3-7, hidroxialquilo C1-6, alquilsulfonilC1-6-alquiloC1-6, alquilsulfanilC1-6- alquiloC1-6, arilalquilo C1-6 o heteroarilalquilo C1-6; en el que: Ra es hidrogeno, alquilo C1-6, cicloalquilo C3-7, cicloalquilC3-7-alquiloC1-4, cicloalquenilo C3-7, cicloalquenilC3-7-alquiloC1-4, haloalquilo C1-6, halocicloalquilo C3-7, hidroxialquilo C1-6, alquilosulfonilC1-6-alquiloC1-6, alquilsulfanilC1-6-alquiloC1-6, arilsulfonilalquilo C1-6, arilo, arilalquilo C1-6, arilalquiloxi C1-6, heteroarilo, heteroarilalquilo C1-6, alquilsulfonamidilC1-6-alquiloC1-6, alcoxicarbonilaminoC1-6-alquiloC1-6, alcoxicarbonilC1-6-alquiloC1-6, alcoxiaminocarbonilC1-6-alquiloC1-6, aminocarbonilalquilo C1-6, alquilaminocarnonilC1-6-alquiloC1-6, carboxialquilo C1-6, heterociclilo, heterociclilalquilo, alquilcarbonilC1-6- alquiloC1-6, heterociclilalquilo C1-6, aminoalquilo C1-6, N-alquilaminoC1-6-alquiloC1-6, N,N-dialquilaminoC1-6-alquiloC1-6, alcoxiC1-6-alquiloC1-6, o heteroarilalquilo C1-6, y Ri es hidrogeno, hidroxi, o alquilo; R3 es hidrogeno o alquilo C1-6; R4 es hidrogeno, alquilo C1-6, hidroxi, amino, heteroalquilo C1-6, heteroalcoxi C1-6, heteroalquilamino C1-6, heterociclilo, heterociclilalquilo C1-6, hidroxicicloalquilo C3-6, cicloalquilC3-6-alquiloC1-6, alquilsulfonilo C1-6, alquilsulfonamido C1-6, arilo, heteroarilo, ariloalquilo C1-6, heteroarilalquilo C1-6, alcoxi C1-6, heteroarilalcoxi C1-6, -(CHRb)r-C(=O)-Rc, -(CHRb)r-O-C(=O)Rc, -(CHRb)r-NH-C(=O)Rc o -SO2-Rc; en el que: Rb es hidrogeno, alquilo C1-6 o heteroalquilo C1-6; Rc es alquilo C1- 6, hidroxi, amino, heteroalquilo C1-6, arilo, arilalquilo C1-6, heteroarilo, o heterociclilo; r es de 0 a 4; X y Y son nitrogeno, o uno de X y Y es nitrogeno y el es CRd; en el que: Rd es hidrogeno, alquilo C1-6, hidroxi, alcoxi C1-6, amino, haloalquilo C1-6, ciano, halo, heteroalquilo C1-6, C(=O)Re o -SO2-Re; en el que Re es hidrogeno o alquilo; W es un enlace, O, S(O)m, CH2 o NRf; en el que: m es de 0 a 2, y Rf es hidrogeno, alquilo C1-6, heteroalquilo C1-6, heterociclilo, hidroxicicloalquilo C3-6, -C(=O)-Rg o -SO2-Rg, en el que Rg es alquilo C1-6, arilo, arilalquilo C1-6, heteroarilo, heteroalquilo C1-6 o heterociclilo; o R4 y Rf junto con los átomos a los que están unidos pueden formar un anillo heterocíclico; A es O, CH2, S(O)n, C(=O), NRh, o CH(ORh), en el que: n es de 0 a 2; y Rh es hidrogeno o alquilo C1-6.
ARP060103657A 2005-08-25 2006-08-23 Inhibidores de la map quinasa p38 y metodos para utilizarla AR056042A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71200905P 2005-08-25 2005-08-25

Publications (1)

Publication Number Publication Date
AR056042A1 true AR056042A1 (es) 2007-09-12

Family

ID=37651018

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103657A AR056042A1 (es) 2005-08-25 2006-08-23 Inhibidores de la map quinasa p38 y metodos para utilizarla

Country Status (16)

Country Link
US (1) US7601726B2 (es)
EP (1) EP1919913A2 (es)
JP (1) JP2009506006A (es)
KR (1) KR101011957B1 (es)
CN (1) CN101243090A (es)
AR (1) AR056042A1 (es)
AU (1) AU2006283940A1 (es)
BR (1) BRPI0614884A2 (es)
CA (1) CA2620254A1 (es)
IL (1) IL189264A0 (es)
MX (1) MX2008002385A (es)
NO (1) NO20080675L (es)
RU (1) RU2008110941A (es)
TW (1) TW200740815A (es)
WO (1) WO2007023110A2 (es)
ZA (1) ZA200801441B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006068760A2 (en) * 2004-11-19 2006-06-29 The Regents Of The University Of California Anti-inflammatory pyrazolopyrimidines
US7585868B2 (en) * 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
US20110160232A1 (en) * 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
WO2009088990A1 (en) 2008-01-04 2009-07-16 Intellikine, Inc. Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) * 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
WO2010036380A1 (en) * 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
DK2358720T3 (en) 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
JP5819831B2 (ja) 2009-08-17 2015-11-24 インテリカイン， エルエルシー 複素環式化合物およびそれらの使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
WO2011143106A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bi - functional pyrazolopyridine compounds
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
GB201009731D0 (en) * 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and their use
NZ612909A (en) 2011-01-10 2015-09-25 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
AR085397A1 (es) 2011-02-23 2013-09-25 Intellikine Inc Combinacion de inhibidores de quinasa y sus usos
MX351754B (es) 2011-04-22 2017-10-27 Signal Pharm Llc Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas.
TWI565709B (zh) 2011-07-19 2017-01-11 英菲尼提製藥股份有限公司 雜環化合物及其用途
US8969363B2 (en) 2011-07-19 2015-03-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AR091790A1 (es) 2011-08-29 2015-03-04 Infinity Pharmaceuticals Inc Derivados de isoquinolin-1-ona y sus usos
JP6342805B2 (ja) 2011-09-02 2018-06-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 置換ピラゾロ［３，４−ｄ］ピリミジンおよびその用途
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013174735A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
SG11201502331RA (en) 2012-09-26 2015-04-29 Univ California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2976086B1 (en) 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
EA201690713A1 (ru) 2013-10-04 2016-08-31 Инфинити Фармасьютикалз, Инк. Гетероциклические соединения и их применения
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2943075C (en) 2014-03-19 2023-02-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
NZ740616A (en) 2015-09-14 2023-05-26 Infinity Pharmaceuticals Inc Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
DE102015012050A1 (de) * 2015-09-15 2017-03-16 Merck Patent Gmbh Verbindungen als ASIC-Inhibitoren und deren Verwendungen
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
CN109923114B (zh) 2016-09-09 2022-11-01 因赛特公司 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途
US10280164B2 (en) 2016-09-09 2019-05-07 Incyte Corporation Pyrazolopyridone compounds and uses thereof
US20180072741A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyrimidine compounds and uses thereof
US20180072718A1 (en) 2016-09-09 2018-03-15 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2018152220A1 (en) 2017-02-15 2018-08-23 Incyte Corporation Pyrazolopyridine compounds and uses thereof
WO2019051199A1 (en) 2017-09-08 2019-03-14 Incyte Corporation 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
LT3755703T (lt) 2018-02-20 2022-10-10 Incyte Corporation N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
US10745388B2 (en) 2018-02-20 2020-08-18 Incyte Corporation Indazole compounds and uses thereof
WO2019164847A1 (en) 2018-02-20 2019-08-29 Incyte Corporation Indazole compounds and uses thereof
US11299473B2 (en) 2018-04-13 2022-04-12 Incyte Corporation Benzimidazole and indole compounds and uses thereof
WO2019212256A1 (ko) * 2018-05-02 2019-11-07 제이더블유중외제약 주식회사 신규한 헤테로 사이클 유도체
US10899755B2 (en) 2018-08-08 2021-01-26 Incyte Corporation Benzothiazole compounds and uses thereof
EP3856348B1 (en) 2018-09-25 2024-01-03 Incyte Corporation Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators
PE20221419A1 (es) 2019-08-06 2022-09-20 Incyte Corp Formas solidas de un inhibidor de hpk1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2232038A1 (de) * 1972-06-30 1974-01-10 Hoechst Ag 3-amino-1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine, ihre herstellung und verwendung
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
GB0100621D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
EA007430B1 (ru) 2001-09-26 2006-10-27 Фармация Италия С.П.А. Производные аминоиндазола, активные в качестве ингибиторов киназ, способ их получения и содержащая их фармацевтическая композиция
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
ATE481402T1 (de) * 2003-02-27 2010-10-15 Palau Pharma Sa Pyrazolopyridin-derivate
US7521447B2 (en) * 2003-03-03 2009-04-21 Array Biopharma Inc. P38 inhibitors and methods of use thereof
SE0301906D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
CN1878773A (zh) 2003-09-05 2006-12-13 神经能质公司 作为crf1受体配位体的杂芳基稠合的吡啶,吡嗪及嘧啶
PL1699800T3 (pl) 2003-12-23 2010-07-30 Novartis Ag Bicykliczne heterocykliczne inhibitory kinazy p-38

Also Published As

Publication number Publication date
IL189264A0 (en) 2008-08-07
AU2006283940A1 (en) 2007-03-01
RU2008110941A (ru) 2009-09-27
ZA200801441B (en) 2009-09-30
JP2009506006A (ja) 2009-02-12
WO2007023110A3 (en) 2007-05-03
MX2008002385A (es) 2008-03-18
US20070054915A1 (en) 2007-03-08
EP1919913A2 (en) 2008-05-14
US7601726B2 (en) 2009-10-13
KR20080040726A (ko) 2008-05-08
CN101243090A (zh) 2008-08-13
BRPI0614884A2 (pt) 2011-04-19
CA2620254A1 (en) 2007-03-01
NO20080675L (no) 2008-03-13
KR101011957B1 (ko) 2011-01-31
TW200740815A (en) 2007-11-01
WO2007023110A2 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
AR056042A1 (es) Inhibidores de la map quinasa p38 y metodos para utilizarla
DK2068921T3 (da) Antistof-antagonister med høj affinitet af interleukin-13-receptor alpha 1
AR064736A1 (es) Agonistas de gpcr
AR054688A1 (es) Alquil-piridinas como inhibidores 11-beta de la diabetes
AR070493A1 (es) Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas.
CO6180507A2 (es) Derivado de 2-piridincarboxamida que tiene efecto activador de gk
AR061341A1 (es) Compuesto de 5-amino-n-[(disustituido-fenil)carbonil-(amino-trifluoro-2-hidroxipropil)-fuorofenil]-1h-pirazol-4-carboxanmida, su uso para la preparacion de un medicamento composicion farmaceutica que lo comprende, proceso y compuestos intermediarios para su preparacion
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
FR2885904B1 (fr) Nouveaux derives du fluorene, compositions les contenant et utilisation
RS53420B (en) MACROCYCLIC COMPOUNDS OF HINOXALINE, WHICH IS AN INHIBITOR OF HCV NS3 PROTEASES WITH OTHER HCV AGENTS
AR064735A1 (es) Agonistas de gpcr y composicion farmaceutica en base al compuesto
AR059445A1 (es) Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados
DK1877379T3 (da) Hydroxybenzamidderivater og anvendelse heraf som inhibitorer af hsp90
CO5720212A1 (es) Composicion de anticuerpo her2
NO20073396L (no) Farmasoytiske kombinasjoner av en angiotensinreceptorantagonist og en NEP-inhibitor
PA8565001A1 (es) Formas de dosificacion de liberacion inmediata que contienen dispersiones de farmaco solido
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
CR8595A (es) Inhibidor del dipeptidil-peptidasa
PE20060934A1 (es) Composicion farmaceutica que comprende un anticuerpo cd20
EA200500146A1 (ru) Моноэтансульфонат 3-z-[1-4-(n-((4-метилпиперазин-1-ил)метилкарбонил)-n-метиламино)анилино)-1-фенилметилен]-6-метоксикарбонил-2-индолинона и его применение в составе фармацевтической композиции
DE602005011593D1 (de) Substituierte diazaspiroä5.5üundecanderivate und deren verwendung als neurokininantagonisten
AR064521A1 (es) Activador de glucoquinasa
CO5680443A2 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion de los mismos y usos de los mismos
NO20084458L (no) IL-8-reseptorantagonister
CY1111983T1 (el) Φαρμακευτικη συνθεση και μεθοδος χρησης αντιμυκητιακου παραγοντα σε συνδυασμο

Legal Events

Date Code Title Description
FB Suspension of granting procedure